Advisory Board of the MIND and MRA programmes

The MIND and MRA Advisory Board consists of representatives for relevant users and authorities. The board meets twice a year to discuss the MRA and MIND programme.

Helle Brøndsted, MSc (pharm), PhD
Product Specialist
DGM Denmark A/S

Troels V. Christensen, MSc (eng.)
Senior Product Life Cycle Manager
H. Lundbeck A/S

Gitte Dyhr, MSc (pharm)
Associate Senior Director, Head of Labelling Committee, Regulatory Affairs 
H. Lundbeck A/S

Jan Fleckner, Ph.D.
Director, Translational Science
Biomarker Expert
Novo Nordisk A/S

Henrik Fylking-Nielsen, MSc (pharm)
Corporate Vice President
Novo Nordisk A/S

Annette Byrholt Hansen, MSc (Pharmacy), PhD
Head of Department, Inspection Laboratory and Inspection Division
Danish Medicines Agency

Jesper Kihl, MSc (Chem. Eng.), Executive Master (coaching and consulting for change)
Vice President, Regulatory Affairs
LEO Pharma A/S

Frank Larsen, MSc (pharmacy), PhD
Chief Specialist, Clinical & Quantitative Pharmacology
H. Lundbeck A/S

Katarina Jelic Maiboe, MSc (Pharm), PhD
Senior Director, Regulatory Affairs
Ascendis Pharma A/S

Morten Munk, BSc Hon (Chem. Eng), Engineering Technology Management (ETM)

Alejandra Mørk, MSc (Pharmacy), PhD
Managing Director
Klifo A/S

Helle Northeved, DVM, PhD
Vice President, Nonclinical Safety Research
H. Lundbeck A/S

Jane Møll Pedersen
Vice President RA Biopharm 2,
Novo Nordisk A/S

Morten Just Petersen, MSc (chemistry), Master of Industrial Drug Development
Chief Operating Officer
Astion Pharma A/S

Kresten Skak, MSc (Biochemistry); PhD (Immunoly)
Translational Scientist, Clinical Pharmacology
LEO Pharma A/S

Merete Schmiegelow, MSc (pharm), MA (comm)
Honorary Ambassador in Regulatory Science

Johan Selmer, MD (medicine)
LEO Pharma A/S

Steffen Thirstrup, MD, PhD (pharmacology)
Director, NDA Regulatory Advisory Board
NDA Advisory Services Ltd.

Nikolai Constantin Brun, MD, PhD
Chief Medical Officer & Director of Division - Medical Evaluation and Biostatistics,
Danish Medicines Agency